• NurExone today reported laboratory results showing consistent anti-inflammatory activity across three separately produced exosome batches.
• The findings support ExoPTEN development for acute spinal cord and optic nerve injuries; they do not establish clinical efficacy.
• Batch consistency also supports planned commercial exosome supply through Exo-Top, alongside a U.S. manufacturing strategy focused on scalability.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NurExone Biologic Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610300829PRIMZONEFULLFEED9856880) on October 30, 2026, and is solely responsible for the information contained therein.